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Abstract
Background: Rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA) are complex
multifactorial diseases caused by environmental influences and an unknown number of predisposing
genes. The present study was undertaken in order to investigate association of polymorphisms in
candidate genes with RA and JRA in German subjects.
Results: Up to 200 unrelated German RA and JRA patients each and 300–400 healthy controls
have been genotyped for HLA-DRB1, TNFa, TNFA -238a/g, TNFA -308a/g, TNFA -857c/t, TNFR1 -609g/
t, TNFR1 P12P, TNFR2 del 15bp, IKBL -332a/g, IKBL -132t/a, IKBL C224R, CTLA4 -318c/t, CTLA4 T17A,
PTPRC P57P, MIF -173g/c, the MIF and IFNG microsatellites as well as for D17S795, D17S807,
D17S1821 by polyacrylamide gel electrophoresis, single-strand conformation polymorphism
analysis, restriction fragment length polymorphism analysis or allele specific hybridization. None of
the investigated genetic markers is associated with both, RA and JRA, but there are some
statistically significant differences between patients and controls that have to be discussed sensibly.
Conclusions: The difficulty in investigating the genetics of complex disorders like RA and JRA may
arise from genetic heterogeneity in the clinically defined disease cohorts (and generally limited
power of such studies). In addition, several to many genes appear to be involved in the genetic
predisposition, each of which exerting only small effects. The number of investigated patients has
to be increased to establish the possibility of subdivison of the patients according their clinical
symptoms, severity of disease, HLA status and other genetic characteristics.
Background
Rheumatoid arthritis in adult patients (RA) is probably
not a single pathogenetic entity leading to a chronic
autoimmune disease resulting in the destruction of joints.
The subforms cannot yet be distinguished clinically. The
worldwide prevalence of RA is about 1% and the precise
etiology is still unknown [1]. Multifactorial origins are
supposed for RA meaning that environmental factors as
well as the contributions of several to many genes appear
to play a role in the development of the disease. The
genetic component is emphasized by a 3–4 fold higher
concordance rate in monozygotic compared to dizygotic
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twins [2]. The manifestation of RA is known to be associ-
ated with certain HLA-DRB1  alleles [3]. The DRB1*04
association has been confirmed for many populations [1].
The associated alleles encode five amino acids at positions
70–74 of the HLA-DRB1 chain. This so-called shared
epitope (SE) comprises of the amino acid sequences
QKRAA, QRRAA and RRRAA [4]. The functional basis of
the SE association has still to be clarified.
Juvenile rheumatoid arthritis (JRA) designates a group of
diseases that have in common chronic idiopathic inflam-
mation of one or more joints. According to the clinical
spectrum JRA can be divided into at least three subtypes
including pauciarticular, polyarticular and systemic onset
with extraarticular manifestations as vasculitis, scleritis
etc. [5]. The pauciarticular type is characterized by the
involvement of one to four joints (monoarticular, oligoar-
ticular), the polyarticular type involves five or more joints.
The presence of autoantibodies and T cell clonality prima-
rily seen in the joints points to autoimmune pathogenesis
[6]. The prevalence of JRA varies worldwide among differ-
ent ethnic and geographically distinct populations [7].
HLA-DRB1*01  and  *04  alleles have been repeatedly
reported to increase the risk for polyarticular JRA in many
populations. HLA-DRB1*04 is highly associated with IgM
rheumatoid factor-positive polyarticular JRA in older chil-
dren [8]. DRB1*01 is associated with pauciarticular dis-
ease onset in younger patients, changing to a polyarticular
course later [9]. Further associated HLA associated alleles
are DRB1*08 and *11 [10].
Since both diseases, RA and JRA, share an autoimmune
background as well as other pathogenetic features, the
same candidate genes can be considered primarily. These
susceptibility genes include an immense number of genes
encoding cytokines, their receptors and other immunore-
levant genes playing possibly significant roles in the
pathogenesis of RA and JRA. A most enigmatic chromo-
somal region for susceptibility to autoimmune disorders
is the HLA region on 6p21. This region harbors also the
tumor necrosis factor alpha (TNFA) locus, for which sev-
eral associations with autoimmune diseases have been
described [11,12]. In addition, the presence of increased
levels of TNF in serum and synovial fluid of RA patients
promoting tissue damage and joint destruction necessi-
tate that this genomic region is investigated. Therefore,
several polymorphisms in the promotor of the TNFA gene
on 6p21 as well as in the TNF receptor genes TNFR1 and
TNFR2 were included. The inhibitor of kappa light chain
gene enhancer in B cells-like gene (IKBL) is also located in
the HLA region and therefore can be considered as a
potent candidate gene for RA/JRA [13].
Cytotoxic T lymphocyte-associated protein 4 (CTLA4) is
expressed on activated T cells and thus it is critically
involved in the immune response [14,15]. Previous stud-
ies on multifactorial disorders like RA, insulin-dependent
diabetes mellitus, multiple sclerosis (MS) and some other
autoimmune diseases investigated in different popula-
tions suggested associations with CTLA4 polymorphisms
[16-21].
Protein-tyrosine phosphatase receptor-type C (PTPRC,
also known as CD45) is expressed on leukocytes and
hematopoietic progenitors [22]. This receptor is involved
in T and B cell activation and in signal transduction by
regulating protein-tyrosine kinases. The protein is found
in multiple isoforms, depending on alternative splicing of
exons 4 (CD45RA), 5 (CD45RB) and 6 (CD45RC)
(CD45RO, exon 4–6 spliced out).
Expression of macrophage migration inhibitory factor
(MIF) correlates well with delayed hypersensitivity and
cellular immunity in humans. MIF activity can be detected
in the synovia of RA patients. The suggested role for MIF
includes mediator function in regulating macrophage
action in host defense [23,24].
Interferon gamma (IFNγ) is produced by T lymphocytes in
response to antigens to which they are sensitized. It dis-
plays antiviral activities [25]. In the first intron of the
IFNG gene a polymorphic (CA)n microsatellite is located
[26]. Microsatellite allele 02 is associated with high levels
of IFNγ production in vitro, which may be due to its asso-
ciation with a linked SNP within a putative NFκB (nuclear
factor kappa B) binding site [27]. Susceptibility to and
severity of RA are associated to different alleles of this mic-
rosatellite [28-31].
IKBL, CTLA4, PTPRC, MIF  and IFNG  only are selected
examples for potent candidate genes for RA association.
They all are involved in immunological processes and are
different parts of signalling cascades. Another approach to
elucidate the genetic background of complex diseases is to
draw parallels from animal models providing important
information concerning which candidate genes or regions
should be studied in humans. This strategy was successful
in the investigation of several human autoimmune dis-
eases like MS or type 1 insulin dependent diabetes melli-
tus [32,33]. A novel RA susceptibility locus on 17q22
homologous to one linked to two rat models of RA was
found by linkage and association mapping [34].
To reveal genetic predisposition factors of the complex
diseases RA and JRA, in this study many polymorphisms
in candidate genes have been genotyped in cohorts of
about 200 patients. Since many of the already reported
associations have not been replicated in all independent
data sets, we compared the allele frequencies in our RABMC Genetics 2004, 5 http://www.biomedcentral.com/1471-2156/5/2
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and JRA cohorts with those of controls in order to contrib-
ute to define general associations.
Results
The results of the HLA-DRB1 typing are shown in figure 1.
The DNA of 367 healthy controls, 190 RA patients and
130 JRA patients has been analysed. The described associ-
ation of the DRB1*04 allele with RA is confirmed in our
cohort (pc < 0.001) [35]. In the group of JRA patients the
DRB1* alleles 08 and 11 are highly represented, but the
differences are not statistically significant.
Figure 2 shows the distribution of alleles of the TNFa mic-
rosatellite. Allele 06 is overrepresented in the group of JRA
patients (17.1% vs. 11.0% in the control group, pc < 0.02).
In the HLA/TNFA region on chromosome 6p21 we deter-
mined allele frequencies of 3 TNFA promotor polymor-
phisms as well as of polymorphisms in the TNFα receptor
genes TNFR1 and TNFR2. Additionally, 3 polymorphisms
in the IKBL gene located also in 6p21 were investigated. In
the TNFA promotor we analysed the -238a/g, -308a/g and
the -857c/t polymorphisms (table 1). No differences of
allele frequencies were found in both groups of patients
compared to the controls. We analysed the promotor pol-
ymorphism -609g/t and a nucleotide exchange a/g at posi-
tion 36 of the coding sequence of the TNFR1 gene. The
base exchange does not result in an amino acid substitu-
tion (P12P). Both polymorphisms are not associated with
RA or JRA (table 1). The allele frequency of a 15 bp
deletion in the promotor of the TNFR2 gene has been
determined for 428 healthy controls, 190 RA patients and
146 JRA patients. The frequency of the deletion (allele 02)
HLA-DRB1 allele frequencies in healthy controls (CON) vs. adult rheumatoid arthritis (RA) and juvenile rheumatoid arthritis  patients (JRA) Figure 1
HLA-DRB1 allele frequencies in healthy controls (CON) vs. adult rheumatoid arthritis (RA) and juvenile rheumatoid arthritis 
patients (JRA).
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is higher in both groups of patients (RA = 32.9%, JRA =
33.3%, controls = 27.5%; p < 0.05). Statistical signifi-
cance, however, is lost after Bonferroni correction of the p
value (table 1, figure 3). In the IKBL gene we analysed the
polymorphisms -332a/g and -132t/a in the promotor and
an amino acid exchange C224R in exon 4. The allele fre-
quencies are shown in table 1. The amino acid substitu-
tion is probably of functional relevance, since cysteine is a
highly reactive and structurally relevant amino acid.
Since the CTLA4 gene is known to play a crucial role in
immunological reactions, we analysed the -318c/t poly-
morphism as well as the T17A exchange in 182 unrelated
RA and 138 JRA patients and 362 healthy controls. The
allele and genotype frequencies of the T17A exchange are
very similar in the patient and in the control groups. A sig-
nificant association, however, was observed for the pro-
motor polymorphism, especially for the group of JRA
patients (pc < 0.001, table 1).
PTPRC and MIF present two other candidate genes for dis-
eases with an immunological background. The c77g
(P57P) polymorphism of the PTPRC (CD45) gene is not
associated with RA or JRA in our cohorts (table 1). DNA
of 347 healthy controls, 195 RA patients and 161 JRA
patients has been investigated. In the promotor of the MIF
gene we analysed an already known SNP (-173g/c) for
390 healthy controls, 283 RA patients and 212 JRA
patients. Allele 02 is underrepresented in the group of RA
patients (16.3% vs. 21.0% in the control group, pc < 0.05)
(table 1). Furthermore a (CATT)n tetranucleotide block
starting at position -794 was analysed. The (CATT)5 allele
appears significantly more frequently in the JRA group
(16.5% vs. 11.0% in the control group, pc < 0.02) (figure
4). The (CATT)7 allele is slightly overrepresented in the RA
group, statistical significance, however, is lost after Bon-
ferroni correction of the p value (figure 4). Evaluation of
the genotypes yielded an overrepresentation of 0507 in
the JRA group (9.4% vs. 4.0% in the control group, pc <
0.06) (figure 4).
Allele frequencies of the TNFa microsatellite in healthy controls (CON) vs. adult rheumatoid arthritis (RA) and juvenile rheu- matoid arthritis patients (JRA) Figure 2
Allele frequencies of the TNFa microsatellite in healthy controls (CON) vs. adult rheumatoid arthritis (RA) and juvenile rheu-
matoid arthritis patients (JRA).
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Furthermore, we genotyped 4 microsatellites, one in
intron 1 of the IFNG gene and 3 in a region on chromo-
some 17 for which an association with RA has been
shown in a rat model as well as in a study with human
DNA. The allele frequencies of the microsatellite in intron
1 of the IFNG gene as well of the three chromosome 17
markers (D17S807, D17S1821, D17S795) do not differ
between the patients and the controls (Figures 5, 6).
Discussion
RA and JRA are two distinct disease entities sharing some
clinical and pathogenetic factors as well as a genetic back-
ground. Both are complex disorders caused by still
unknown environmental influences and by probably
manifold variations in an unknown number of predispos-
ing genes. To evaluate genetic susceptibility loci several
immunorelevant polymorphisms have been genotyped
for both cohorts (RA and JRA) and compared to healthy
controls.
The manifestation of RA and JRA is associated with certain
HLA-DRB1  alleles [3]. The association of RA with the
DRB1*04 allele was first defined by Stastny et al. [36]
Subsequently, this association has been observed in a
majority of populations belonging to different ethnic
groups [1]. The HLA-DRB1 typing of our RA cohort con-
firmed this association. Thus our cohort of RA patients
comprises a representative random sample.
The association of HLA-DRB1*01  and  *04  alleles
described in the literature is not obvious in the JRA cohort
presented here [8,9]. Possible explanations include that
the representation of different subclasses in this heteroge-
nous group of patients is not similar to previous collec-
tions because of the limited number of participating
patients. The HLA-DRB1*08  and  *11  alleles, however,
appear more frequently in the JRA group than in the con-
trol group corresponding to literature data [10]. Since the
HLA region on 6p21 is highly interesting concerning
autoimmune diseases and because of the presence of
Allele frequencies of the TNFRII 15 bp deletion in the promotor in healthy controls (CON) vs. adult rheumatoid arthritis (RA)  and juvenile rheumatoid arthritis patients (JRA) Figure 3
Allele frequencies of the TNFRII 15 bp deletion in the promotor in healthy controls (CON) vs. adult rheumatoid arthritis (RA) 
and juvenile rheumatoid arthritis patients (JRA).
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increased levels of TNFα in serum and synovial fluid of RA
patients promoting tissue damage and joint destruction,
several polymorphisms in the promotor of the TNFA gene
on 6p21 as well as in the TNF receptor genes TNFR1 and
TNFR2  were investigated. The TNFA  locus is located
within the HLA class III region. Five microsatellite markers
(a-e) have been described [37]. TNFa was analyzed in this
study. The allele frequencies are similar to those of other
studies [38]. TNFa2 is the most frequent allele in both
groups of patients (RA and JRA) as well as in the control
group, but a significant difference of the frequency
between patients and controls has not been observed.
a,b: Allele and genotype frequencies of the MIF microsatellite in healthy controls (CON) vs. adult rheumatoid arthritis (RA) and  juvenile rheumatoid arthritis patients (JRA) Figure 4
a,b: Allele and genotype frequencies of the MIF microsatellite in healthy controls (CON) vs. adult rheumatoid arthritis (RA) and 
juvenile rheumatoid arthritis patients (JRA).
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Table 2: Allele and genotype frequencies
allele 01 (%) allele 02 (%) pc
TNFA-238a/g
CON (n = 375) 726 (96.8) 24 (3.2)
RA (n = 170) 323 (95.0) 17 (5.0) n.s.
JRA (n = 130) 254 (97.7) 6 (2.3) n.s.
TNFA-308a/g
CON (n = 312) 527 (84.5) 97 (15.5)
RA (n = 151) 257 (85.1) 45 (14.9) n.s.
JRA (n = 122) 202 (82.8) 42 (17.2) n.s.
TNFA-857c/t
CON (n = 415) 738 (88.9) 92 (11.1)
RA (n = 191) 343 (89.8) 39 (10.2) n.s.
JRA (n = 170) 299 (87.9) 41 (12.1) n.s.
TNFR1-609g/t
CON (n = 324) 384 (59.3) 264 (40.7)
RA (n = 173) 221 (63.9) 125 (36.1) n.s.
JRA (n = 136) 166 (61.0) 106 (39.0) n.s.
TNFR1 P12P
CON (n = 334) 361 (54.0) 307 (46.0)
RA (n = 166) 167 (50.3) 165 (49.7) n.s.
JRA (n = 132) 154 (58.3) 110 (41.7) n.s.
TNFR2 del15
CON (n = 428) 621 (72.5) 235 (27.5)
RA (n = 190) 255 (67.1) 125 (32.9) 0.1
JRA (n = 146) 195 (66.7) 97 (33.3) 0.1
IKBL-332a/g
CON (n = 389) 711 (91.4) 67 (8.6)
RA (n = 184) 333 (90.5) 35 (9.5) n.s.
JRA (n = 170) 316 (92.9) 24 (7.1) n.s.
IKBL-132t/a
CON (n = 389) 555 (71.3) 223 (28.7)
RA (n = 177) 263 (74.3) 91 (25.7) n.s.
JRA (n = 170) 232 (68.2) 108 (31.8) n.s.
IKBL C224R
CON (n = 379) 701 (92.5) 57 (7.5)
RA (n = 189) 359 (95.0) 19 (5.0) n.s.
JRA (n = 169) 320 (94.7) 18 (5.3) n.s.
CTLA4-318c/t
CON (n = 362) 674 (93.1) 50 (6.9)
RA (n = 284) 504 (88.7) 64 (11.3) 0.01
JRA (n = 197) 342 (86.8) 52 (13.2) 0.001
CTLA4 T17A
CON (n = 362) 455 (62.8) 269 (37.2)
RA (n = 284) 346 (60.9) 222 (39.1) n.s.
JRA (n = 197) 255 (64.7) 139 (35.3) n.s.
PTPRC P57P
CON (n = 347) 684 (98.6) 10 (1.4)
RA (n = 195) 382 (97.9) 8 (2.1) n.s.
JRA (n = 161) 316 (98.1) 6 (1.9) n.s.
MIF-173g/c
CON (n = 390) 616 (79.0) 164 (21.0)
RA (n = 168) 285 (84.8) 51 (15.2) 0.05
JRA (n = 150) 227 (75.7) 73 (24.39) n.s.
CON: healthy controls, RA: adult RA patients, JRA juvenile RA patientsBMC Genetics 2004, 5 http://www.biomedcentral.com/1471-2156/5/2
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TNFa2 was found to be associated with high TNFα pro-
duction [39]. Zake et al. found evidence for a positive
association of this allele with JRA [5]. The contradictory
data may result from the different origins of the patients.
TNFa6 is significantly overrepresented in the JRA group of
this study. A strong association of TNFa6 with RA in
DRB1*04-negative haplotypes was also shown by Tuokko
et al. [40] The mechanisms behind the TNFa6 association
with RA has not been clarified yet, but in patients with
insulin-dependent diabetes mellitus the TNFa6 allele has
been reported to be associated with decreased TNFα secre-
tion, wheras the TNFa2 allele was associated with high
TNFα secretion capacity [39]. The coherency of RA-associ-
ated TNFa6 and low TNFα secretion is not in accordance
with the known involvement of this cytokine in tissue
destruction in RA, but the complex pathogenic mecha-
nisms are not understood in detail until now.
In the TNFA promotor are described at least 11 polymor-
phisms and numerous studies have been undertaken to
determine whether these polymorphisms have any func-
tional significance [11,12,41]. The results of these studies,
however, have been conflicting. Some authors conclude
that  TNFA  genotypes influence immunologic diseases
while others suggest that TNFA promotor polymorphisms
exert no functional effects but exist only because they are
in linkage disequilibrium with HLA alleles [42,43]. In this
study, three promotor polymorphisms of TNFA have been
chosen to analyse, -857c/t, -308a/g and -238a/g. No asso-
ciation was found for any of those polymorphisms with
RA or JRA. The obtained allele frequencies are comparable
with the results of other studies on Caucasians [43-45]. In
contrast, Seki et al. found that the frequency of the -857t
allele in RA patients is significantly higher than in the con-
trols [46]. However, the DRB1*0405 allele, which is in
linkage disequilibrium with the -857t allele, is more
strongly associated with disease susceptibility than the -
857t allele. Thus the authors concluded that a susceptibil-
ity gene to RA is more closely linked to the HLA-DRB1
locus than to the TNFA locus.
Since TNFα acts via binding to cell surface receptors I and
II, their genes are interesting candidates for RA.
Furthermore animal models have shown that mice defi-
cient in TNFR have a more severe early inflammatory
response [47]. The gene of the TNF receptor 1 (TNFR1) is
localized on chromosome 12p13 and consists of 10 exons
[48]. Each of the four protein repeats comprising the
extracellular ligand binding domain and characterizing a
receptor superfamily is interrupted by an intron [48]. The
Allele frequencies of the IFNG microsatellite in healthy controls (CON) vs. adult rheumatoid arthritis (RA) and juvenile rheu- matoid arthritis patients (JRA) Figure 5
Allele frequencies of the IFNG microsatellite in healthy controls (CON) vs. adult rheumatoid arthritis (RA) and juvenile rheu-
matoid arthritis patients (JRA).
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a-c: Allele frequencies of the D17S795, D17S807 and D17S1821 microsatellites in healthy controls (CON) vs. adult rheumatoid  arthritis (RA) and juvenile rheumatoid arthritis patients (JRA) Figure 6
a-c: Allele frequencies of the D17S795, D17S807 and D17S1821 microsatellites in healthy controls (CON) vs. adult rheumatoid 
arthritis (RA) and juvenile rheumatoid arthritis patients (JRA).
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promotor polymorphism -609g/t and a nucleotide
exchange a/g at position 36 of the coding sequence of the
TNFR1 gene were analysed in this study [48,49]. The base
exchange does not result in an amino acid substitution
(P12P). Both polymorphisms are not associated with RA
or JRA. This result confirms the findings of Barton et al.
[50].
The gene of the TNF receptor 2 (TNFR2) is localized on
chromosome 1p36.2. The 10 exons span 26 kb [51]. In
the 5' untranslated region a 15 bp insertion/deletion pol-
ymorphism is located between positions -363 to -349
[49]. In this polymorphic region there is similarity to a
putative transcription factor binding site. A regulatous
function could not be ascribed to this section [52]. Thus
the deletion is probably not of functional relevance. The
allele frequencies of the deletion are higher in both groups
of patients, but statistical significance is lost after Bonfer-
roni correction. Barton et al. [50] and Dieude et al. [53]
presented evidence that TNFR2 plays a major role in a
subset of families with multiple cases of RA [50,53]. A pol-
ymorphism in exon 6 of the TNFR2 gene has been ana-
lysed [50,53]. The cohorts in this study did not encompass
a sufficient number of patients with family history to war-
rant investigation of this specific exonic marker.
Near the TNF cluster at the telomeric end of the MHC on
chromosome 6p21.3 the IKBL gene is located coding for a
381 amino acid protein and spanning 13.5 kb of genomic
DNA [13]. The protein contains ankyrin motifs similar to
those of the I-kappa-B (IκB) family of proteins. Since IKBL
shares homology with other members ot the IκB family, it
may interact with NFκB and regulate acute phase proteins
such as TNFα [54]. Thus IKBL is not only an interesting
candidate gene for RA susceptibility because of the posi-
tion on 6p21.3. In this study two promotor polymor-
phisms as well as a non-synonymous substitution
(C224R) have been analysed [55]. The amino acid
exchange lies in a predicted phosphorylation site and it
possibly alters the function of the IκBL protein. None of
the three polymorphisms is associated with RA or JRA in
our cohorts. Further analysis of patients with other
autoimmune diseases may elucidate the functional mean-
ing especially of the amino acid substitution.
CTLA4 is expressed on activated T cells binding to the lig-
ands, B7-1 and B7-2 and it is predicted to down-regulate
T cell function [56,57]. These observations suggest that
the CTLA4 / B7 interaction plays a critical role in regulat-
ing self-tolerance and in susceptibility to autoimmune
diseases. The CTLA4 gene comprises 3 exons in addition
to the leader sequence and maps to chromosome 2q33
[58]. Three polymorphisms have been described in the
CTLA4 gene: a microsatellite (AT)n at position 642 of the
3'untranslated region of exon 4 and two SNPs, in exon 1
a a49g base exchange leading to an amino acid substitu-
tion T17A in the leader sequence and a c/t transition at
position -318 of the promoter sequence [59-61]. Studies
on RA as well as on insulin-dependent diabetes mellitus
and some other autoimmune diseases suggest an associa-
tion with these CTLA4 polymorphisms [16-21]. In this
study we analysed the -318c/t polymorphism and the
a49g exchange. A remarkable difference of the allele
frequency of the promotor polymorphism was found in
the group of RA patients and even more clearly in the
group of JRA patients. The distribution of alleles of the
more interesting amino acid exchange, however, does not
show differences between patients and controls. Further
investigations are needed to clarify the importance of
CTLA4 as a susceptibility gene for RA and/or JRA.
Furthermore, the PTPRC gene has been investigated here
[22]. PTPRC is localized on chromosome 1q31-q32 and
consists of 35 exons. The gene encodes a 180–220 kDa
glycoprotein expressed on leukocytes and hematopoietic
progenitors [22]. This receptor is involved in T and B cell
activation and in signal transduction by regulating pro-
tein-tyrosine kinases. Because of this involvement in
immunological processes, the gene is another important
candidate for RA predisposition. The protein exists in
multiple isoforms, depending on alternative splicing of
exons 4 (CD45RA), 5 (CD45RB) and 6 (CD45RC) (in
CD45RO exons 4–6 are spliced out). The already known
c77g (P57P) transition in exon 4 was analysed in our
cohorts. This polymorphism does not change the amino
acid sequence, but it is probably part of a motif necessary
for splicing of CD45RA. The expression of CD45RA is
increased in 77c/g heterozygous individuals [62]. The fre-
quency of 77c/g heterozygotes is slightly increased in both
groups of RA patients compared to the controls, but the
result is not statistically significant. Maybe this gene is
more important for predisposition to other autoimmune
diseases. The c77g polymorphism has been investigated in
several studies with patients suffering from MS. The
reported results, however, are controversial. Jacobsen et
al. demonstrated an association of this polymorphism
with MS in three families whereas 3 studies excluded MS
association later on [62-65].
MIF is found in the synovia of RA patients. The expression
of MIF at sites of inflammation suggested a role in
regulating the function in host defense. Expression of MIF
correlates well with delayed hypersensitivity and cellular
immunity in humans [23,24]. The MIF gene covers only
less than 1 kb and has three exons separated by small
introns of 189 and 95 bp [66]. So far 4 polymorphisms
have been revealed in the MIF  gene: a tetranucleotide
repeat (CATT)n beginning at nucleotide position -794, a g/
c exchange in the promotor at position -173, a t/c substi-
tution in intron 1 and a c/g substitution in intron 2 [67].BMC Genetics 2004, 5 http://www.biomedcentral.com/1471-2156/5/2
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The (CATT)n repeat is functionally relevant and it affects
the activity of the MIF promotor. 5, 6, 7 and 8 consecutive
CATT repeat units have been found. The (CATT)5 allele
has the lowest level of basal and stimulated MIF promotor
activity in vitro [68]. In the JRA cohort presented here, the
(CATT)5 allele is overrepresented compared to the con-
trols and the RA group as well as the 0507 genotype. The
presence of the low expression-associated (CATT)5 allele
correlates with low disease severity in RA patients [68].
Donn et al. demonstrated that the MIF-173g/c variants
result in altered expression of MIF in a cell type-specific
manner. Serum levels of MIF are also significantly higher
in individuals carrying a MIF-173c allele [69]. In this
study the -173g/c polymorphism has been analysed. The
c allele appears more frequently in the control group and
in the group of JRA patients. The frequency of this allele in
the RA group is statistically significantly lower.
IFNγ is produced by T lymphocytes in response to anti-
gens. In the first intron of the IFNG gene on 12q14 a pol-
ymorphic (CA)n  microsatellite is located [26].
Microsatellite allele 02 is associated with high levels of
IFNγ production in vitro. Khani-Hanjani et al. described
susceptibility to and severity of RA are associated to differ-
ent alleles of this microsatellite [28]. In our study no dif-
ferences in the distribution of alleles was found between
patients and controls. A similar result has been observed
by Constantin et al. [70]. Thus the role of IFNG in RA sus-
ceptibility is not clear today.
Recently, a novel RA susceptibility locus on 17q22 homol-
ogous to one linked to two rat models of RA was found by
linkage and association mapping [34]. We analysed three
highly polymorphic microsatellites in this region, but no
one is associated with the disease. CD79b, a member of
the immunoglobulin superfamily, is located in this
region. Owing to the involvement in lymphocyte activa-
tion, it is a possible candidate gene for RA predisposition.
Another gene located in this region is ICAM-2, which par-
ticipates in the regulation of apoptosis. It is a cell surface
adhesion molecule expressed on the endothelium and is
involved in leukocyte recruitment into tissues [71]. TNFα
and other cytokines are able to down-regulate ICAM-2
expression on the transcriptional level.
Conclusions
RA and JRA are complex diseases the manifestation of
which is depending on the presence of an unknown
number of predisposing alleles in a susceptible individ-
uum. A gene of major effect has not been identified, but
several statistically significant results have to be
interpreted sensibly. Some of the investigated biallelic
polymorphisms are not informative because of the low
frequency of the second allele. Thus these markers are
considered as not suitable for detecting genetic associa-
tion. Clearly in the cases of 'negative' results, association
with the genes tested can formally not be excluded,
because other unlinked variations within the gene(s) in
question may be pathogenetically relevant (and therefore
also associated) in our cohorts. The number of investi-
gated patients has to be increased to establish the possibil-
ity of subdivison of the cohorts according their clinical
symptoms, severity of disease, HLA status and also with
respect to individual genetic factors.
Patients and methods
Patients and controls
More than 200 unrelated RA patients and more than 200
unrelated JRA patients of German origin were attended by
the department of rheumatology of the University Hospi-
tal (Magdeburg, Germany) and the department of pediat-
rics of the Karl-Thiem Hospital (Cottbus, Germany). The
adult RA patients met the American College of Rheuma-
tology (ACR) criteria for RA [72]. The JRA patients were
recruited according the classification of childhood arthri-
tis [73]. The male/female rate was 1:4 (RA) and 1:2 (JRA);
the mean age at onset was 48.6 (14–79; RA) and 10.3 (1–
22; JRA) years.
The department of transplantation and immunology of
the University Hospital Eppendorf (Hamburg, Germany)
provided peripheral blood samples as well as informed
consent from more than 400 healthy blood donors. The
mean age of the participants was 39.3 (20–70) years. The
male/female rate was 1.4 [74].
PCR and RFLP analysis
Polymerase chain reactions (PCRs) were carried out in a
final volume of 12.5 µl with 50 ng of DNA, 200 µM dNTP,
1 U Taq Polymerase and 0.1 µCi [α32P]-dCTP. Primer
sequences, PCR conditions, fragment sizes and restriction
enzymes utilized are shown in Additional File 1. PCR
cycling started with initial denaturation for 5 minutes at
94°C. The annealing temperature of the first cycle was
6°C, of the second cycle 3°C higher than the remaining
26 cycles to achieve high specificity at the beginning of the
reaction and to increase the quantity of PCR products in
the following cycles. The annealing time was 1 minute.
Extension was performed at 72°C for 1 minute with final
extension of 5 minutes. Restriction enzyme digestion of
PCR products >200 bp was performed according to the
manufacturer's recommendations. PCR products were
electrophoresed by loading restricted fragments onto ver-
tical denaturing or non-denaturing 6% polyacrylamide
(PAA) gels.
SSCP and sequence analysis
The native PAA gels used for single-strand conformation
polymorphism (SSCP) analysis were carried out at 4°C.
Each PCR system was tested under two different gel con-BMC Genetics 2004, 5 http://www.biomedcentral.com/1471-2156/5/2
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ditions. 5% glycerine was added to the first gel, 2.5% glyc-
erine and 1 M urea to the second. Results were
documented by autoradiography. Direct sequencing of
PCR products was performed on a 373A sequencing auto-
mate using the BigDye Terminator Cycle Sequencing Kit
(Applied Biosystems).
Allele specific hybridization
Sequences of oligonucleotides used for allele specific
hybridization are shown in Additional File 1. These
oligonucleotides were designed to locate the discriminat-
ing single nucleotide exchange in the middle. PCR frag-
ments were denatured in 0.4 M NaOH and transferred
onto nylon membranes, utilizing a robot work station
(Biomek 2000, Beckman). Two filters were hybridized in
parallel, each with one of the allele-specific oligonucle-
otides. For control the hybridization probe was stripped
and the filters rehybridized with the second oligonucle-
otide. Results were documented by autoradiography. Oli-
gonucleotide sequences for HLA-DRB1 genotyping were
designed according to published sequences or as
described previously [75,76].
Statistics
Comparisons of the frequencies of alleles were performed
by Chi-square test in a 2 × 2 contingency table. Pc values
are corrected for the number of all alleles tested using
Bonferroni correction.
List of abbreviations
CTLA4 cytotoxic T lymphocyte-associated protein 4
IFNγ interferon gamma
IKBL inhibitor of kappa light chain gene enhancer in B
cells-like gene
JRA juvenile rheumatoid arthritis
MIF macrophage migration inhibitory factor
MS multiple sclerosis
NFκB nuclear factor kappa B
PAA polyacrylamide
PCR polymerase chain reaction
PTPRC protein-tyrosine phosphatase receptor-type C
RA rheumatoid arthritis
SE shared epitope
SSCP single-strand conformation polymorphism
TNFα tumor necrosis factor alpha
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